M. Schuurbiers

Immune defects in patients with pulmonary Mycobacterium abscessus disease without cystic fibrosis

M. Netea, W. Hoefsloot, M. Boeree, 2020, ERJ Open Research.

Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II–IIIA NSCLC patients

T. C. Linders, K. L. Ramkisoensing, D. van den Broek, 2022, Molecular oncology.

Modeling strategies to analyse longitudinal biomarker data: An illustration on predicting immunotherapy non-response in non-small cell lung cancer

M. IJzerman, M. M. van den Heuvel, S. Burgers, 2022, Heliyon.

Cell-Free DNA at Diagnosis for Stage IV Non-Small Cell Lung Cancer: Costs, Time to Diagnosis and Clinical Relevance

W. V. van Harten, V. Retèl, D. van den Broek, 2022, Cancers.

Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC

A. Lovejoy, D. van den Broek, K. Monkhorst, 2022, Journal for ImmunoTherapy of Cancer.

Diagnosing non-small cell lung cancer by exhaled-breath profiling using an electronic nose: a multicentre validation study.

B. E. van den Borne, S. Kort, J. van der Palen, 2022, Chest.

Serum tumor markers for response prediction and monitoring of advanced lung cancer: A review focusing on immunotherapy and targeted therapies.

S. Holdenrieder, H. V. van Rossum, D. Lang, 2023, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

Clinical perspectives on serum tumor marker use in predicting prognosis and treatment response in advanced non-small cell lung cancer.

H. V. van Rossum, M. Schuurbiers, M. M. van den Heuvel, 2023, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.